CL2021000008A1 - Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017) - Google Patents

Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)

Info

Publication number
CL2021000008A1
CL2021000008A1 CL2021000008A CL2021000008A CL2021000008A1 CL 2021000008 A1 CL2021000008 A1 CL 2021000008A1 CL 2021000008 A CL2021000008 A CL 2021000008A CL 2021000008 A CL2021000008 A CL 2021000008A CL 2021000008 A1 CL2021000008 A1 CL 2021000008A1
Authority
CL
Chile
Prior art keywords
heparinoid
cancer treatment
divisional application
divisional
cancer
Prior art date
Application number
CL2021000008A
Other languages
English (en)
Inventor
Stephen Marcus
Original Assignee
Cantex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantex Pharmaceuticals Inc filed Critical Cantex Pharmaceuticals Inc
Publication of CL2021000008A1 publication Critical patent/CL2021000008A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2021000008A 2012-05-09 2021-01-04 Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017) CL2021000008A1 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261644623P 2012-05-09 2012-05-09
US201261644556P 2012-05-09 2012-05-09
US201261648043P 2012-05-16 2012-05-16
US201261653362P 2012-05-30 2012-05-30
US201261664611P 2012-06-26 2012-06-26
US201261668709P 2012-07-06 2012-07-06
US201261678053P 2012-07-31 2012-07-31
US201261702207P 2012-09-17 2012-09-17
US201261724836P 2012-11-09 2012-11-09

Publications (1)

Publication Number Publication Date
CL2021000008A1 true CL2021000008A1 (es) 2021-06-11

Family

ID=49549076

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014003017A CL2014003017A1 (es) 2012-05-09 2014-11-07 Uso de un heparinoide interactuando con pf4 para tratar efecto mielodepresivo
CL2021000008A CL2021000008A1 (es) 2012-05-09 2021-01-04 Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2014003017A CL2014003017A1 (es) 2012-05-09 2014-11-07 Uso de un heparinoide interactuando con pf4 para tratar efecto mielodepresivo

Country Status (21)

Country Link
US (6) US9271999B2 (es)
EP (2) EP3785720A1 (es)
JP (3) JP6177885B2 (es)
KR (2) KR102165348B1 (es)
CN (3) CN104411316B (es)
AU (1) AU2013260101B2 (es)
BR (1) BR112014028094B1 (es)
CA (2) CA3122808A1 (es)
CL (2) CL2014003017A1 (es)
DK (1) DK2846809T3 (es)
EA (1) EA029382B1 (es)
ES (1) ES2848050T3 (es)
HK (1) HK1207574A1 (es)
HU (1) HUE053247T2 (es)
IL (1) IL235593B (es)
LT (1) LT2846809T (es)
MX (2) MX370567B (es)
PL (1) PL2846809T3 (es)
PT (1) PT2846809T (es)
SG (3) SG10201603059YA (es)
WO (1) WO2013169355A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053247T2 (hu) 2012-05-09 2021-06-28 Cantex Pharmaceuticals Inc Mieloszuppresszió kezelése
SG11201603081WA (en) * 2013-10-22 2016-05-30 Cantex Pharmaceuticals Inc Methods of treating and preventing radiation damage
WO2015142924A1 (en) 2014-03-17 2015-09-24 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
WO2016144635A1 (en) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a ras mutation
MY181892A (en) 2015-07-13 2021-01-12 Beyondspring Pharmaceuticals Inc Plinabulin compositions
SG11201806583XA (en) 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
MY201811A (en) 2017-02-01 2024-03-19 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
CN107569486A (zh) * 2017-08-23 2018-01-12 北京京佑奇康生物科技有限公司 孟鲁司特钠治疗血小板减少症的新用途
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
SG11202006985TA (en) * 2018-01-24 2020-08-28 Beyondspring Pharmaceuticals Inc Composition and method for reducing thrombocytopenia via the administration of plinabulin
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
MA54821A (fr) * 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiques
AU2020259406A1 (en) 2019-04-17 2021-11-04 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
WO2021041532A1 (en) * 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
EP4058018A4 (en) * 2019-11-13 2023-06-21 Taiho Pharmaceutical Co., Ltd. METHODS OF TREATMENT OF LSD1-RELATED DISEASES AND DISORDERS USING LSD1 INHIBITORS
WO2021207697A1 (en) 2020-04-10 2021-10-14 Cantex Pharmaceuticals, Inc. Treatment of acute lung injury
EP4182452A1 (en) 2020-07-14 2023-05-24 Optimvia, LLC Methods for synthesizing non-anticoagulant heparan sulfate
KR20230058289A (ko) 2021-10-21 2023-05-03 숙명여자대학교산학협력단 혈액암 치료를 위한 글리세오플빈 병용요법

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2374910A1 (fr) 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US5804374A (en) 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
FR2553287B1 (fr) 1983-10-18 1986-09-12 Choay Sa Compositions a base de mucopolysaccharides ou d'oligosaccharides, notamment a base de fractions ou fragments d'heparine, appropriees au traitement de desordres de la proliferation cellulaire
DE3422518A1 (de) 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen Heparin-derivate, verfahren zu ihrer herstellung, diese enthaltende arzneimittel und ihre verwendung bei der behandlung von fettstoffwechselstoerungen
FR2584606A1 (fr) 1985-07-12 1987-01-16 Dropic Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
IT1234826B (it) 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
AU7681091A (en) 1990-04-05 1991-10-30 John R Hoidal Method and medicament for prevention or medication of human leucocyte elastase-mediated pulmonary diseases
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
IT1254216B (it) 1992-02-25 1995-09-14 Opocrin Spa Derivati polisaccaridici di eparina, eparan solfato, loro frazioni e frammenti, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
AU3938093A (en) 1992-04-02 1993-11-08 Baker Norton Pharmaceuticals, Inc. Method and composition for treating antigen-induced and exercise-induced asthma
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5306724A (en) 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
GB2270841A (en) 1992-09-09 1994-03-30 Merck & Co Inc Compositions for Treating vascular restenosis
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5696100A (en) 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
AU6246394A (en) 1993-02-22 1994-09-14 Cavalier Pharmaceuticals, Inc. Use of heparin to inhibit interleukin-8
SE9302135D0 (sv) 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
US5840707A (en) 1993-10-04 1998-11-24 Albany Medical College Stabilizing and delivery means of biological molecules
US5994318A (en) 1993-10-04 1999-11-30 Albany Medical College Cochleate delivery vehicles
EP0758247A4 (en) 1994-05-06 1997-08-20 Glycomed Inc O-DESULFATED HEPARIN DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
JP4097044B2 (ja) 1996-07-29 2008-06-04 パリンジェニックス，インコーポレイテッド Ｏ―脱硫酸化ヘパリンで喘息を治療する方法
US6154502A (en) 1996-08-22 2000-11-28 Intel Corporation Signal constellation slicer
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
CA2281224A1 (en) 1997-02-15 1998-08-20 Proscript, Inc. Treatment of infarcts through inhibition of nf-kappab
EP0986401B1 (en) 1997-05-30 2004-02-25 Arch Development Corporation P-selectin translocation to vascular epithelial lumen by ionizing radiation
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
CA2351067A1 (en) 1998-11-13 2000-05-25 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US6514502B1 (en) 1999-01-26 2003-02-04 Schering-Plough Veterinary Corporation Propagation of bovine cononavirus in chinese hamster ovary cells
AU763042B2 (en) 1999-09-13 2003-07-10 Charlotte-Mecklenburg Hospital Authority Method of inhibiting NF-kappaB with heparin
US7781416B2 (en) 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US6489311B1 (en) 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
SK12772003A3 (sk) * 2001-04-18 2004-07-07 Prometic Biosciences Inc. Stredne dlhé mastné kyseliny, glyceridy a analógy ako faktory prežitia a aktivácie neutrofilov
US20040072796A1 (en) 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
JP2005535665A (ja) 2002-07-09 2005-11-24 ザ スクリプス リサーチ インスティテュート 虚血および再灌流損傷を防止する方法
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
WO2004050673A2 (en) 2002-11-27 2004-06-17 Massachusetts Institute Of Technology Methods for synthesizing polysaccharides
US20040180812A1 (en) * 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease
CN1805743A (zh) 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
WO2005089365A2 (en) 2004-03-16 2005-09-29 The General Hospital Corporation Treatment and prevention of abnormal cellular proliferation
EP2407169A1 (en) * 2004-04-22 2012-01-18 Celator Pharmaceuticals, Inc. Combination formulations of anthracycline agents and cytidine analogs
US20050261241A1 (en) 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US7468358B2 (en) * 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
US20050282775A1 (en) * 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US20060040896A1 (en) 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
JP2006076968A (ja) 2004-09-10 2006-03-23 Seikagaku Kogyo Co Ltd 生理活性分子含有架橋ヘパリンゲル組成物
MX2008000974A (es) 2005-07-22 2008-03-27 Univ California Composiciones de heparina e inhibicion de selectina.
WO2007019554A2 (en) 2005-08-08 2007-02-15 Momenta Pharmaceuticals, Inc. Polysaccharides for delivery of active agents
EA016168B1 (ru) 2005-09-30 2012-02-28 Такара Био Инк. Способ получения т-клеточной популяции и ее применение
US20090054373A1 (en) 2005-12-16 2009-02-26 Dnp Canada Inc. Chitin derivatives for hyperlipidemia
WO2007115372A1 (en) 2006-04-10 2007-10-18 Monash University A method of modulating beta-amyloid peptide production
JP2009544711A (ja) 2006-07-26 2009-12-17 イントレクソン コーポレイション 疾病の治療方法及び疾病治療用組成物
WO2008085562A2 (en) 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
US20090054374A1 (en) 2007-02-28 2009-02-26 Paringenix, Inc. Methods of treating acute exacerbations of chronic obstructive pulmonary disease
WO2008150532A1 (en) * 2007-06-01 2008-12-11 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
CA2694189A1 (en) 2007-07-23 2009-01-29 University Of Utah Research Foundation Method for blocking ligation of the receptor for advanced glycation end-products (rage)
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US20090238852A1 (en) 2008-03-21 2009-09-24 University Of Utah Research Foundation Methods for controlling intracellular calcium levels associated with an ischemic event
BRPI0909849A2 (pt) 2008-04-04 2015-10-06 Univ Utah Res Found éteres semi-sintéticos de glicosaminoglicosanos e métodos para fazê-los e usá-los
US8476249B2 (en) * 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
WO2011038901A1 (en) 2009-09-29 2011-04-07 Activaero Gmbh Improved method for treatment of patients with cystic fibrosis
EP2550004A4 (en) 2010-03-12 2014-07-02 Univ Australian SUBSTITUTE THERAPY WITH HEPARAN SULFATE
SG184092A1 (en) * 2010-03-24 2012-10-30 Biorealites Prophylaxis of colorectal and gastrointestinal cancer
EP3153173A1 (en) 2010-06-28 2017-04-12 Stemtech International, Inc. Methods and compositions for enhancing stem cell mobilization
EP2670396A1 (en) * 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
US20120196828A1 (en) 2011-02-01 2012-08-02 Paringenix, Inc. Sensitization of cancer cells to treatment
WO2013016181A1 (en) 2011-07-22 2013-01-31 Paringenix, Inc. Compositions and methods for anti-coagulation
BR112014027333A2 (pt) 2012-05-01 2017-07-18 Univ Duke composição, métodos de tratamento ou melhora, de prevenção, e, de diagnóstico de uma condição prejudicial que está associada com o teor elevado de sulfato de heparano em um indivíduo que foi o receptor de um órgão, tecido ou células transplantados
HUE053247T2 (hu) 2012-05-09 2021-06-28 Cantex Pharmaceuticals Inc Mieloszuppresszió kezelése
KR20160023638A (ko) 2013-02-28 2016-03-03 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 줄기세포를 이동하기 위한 방법 및 조성물
SG11201603081WA (en) 2013-10-22 2016-05-30 Cantex Pharmaceuticals Inc Methods of treating and preventing radiation damage
US20160296552A1 (en) 2013-10-24 2016-10-13 Cantex Pharmaceuticals, Inc. Treating Bacterial Infections of the Lung
WO2015142924A1 (en) 2014-03-17 2015-09-24 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
US20160243168A1 (en) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Adoptive cell transfer methods
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
US20170106011A1 (en) 2015-10-20 2017-04-20 Cantex Pharmaceuticals, Inc. Methods of treating traumatic brain injury and sequelae
WO2017123549A1 (en) 2016-01-11 2017-07-20 Cantex Pharmaceuticals, Inc. Methods of treating or preventing graft-versus-host disease using hmgb1-interacting heparinoids

Also Published As

Publication number Publication date
IL235593B (en) 2019-06-30
US8734804B2 (en) 2014-05-27
JP6726252B2 (ja) 2020-07-22
CN108498532A (zh) 2018-09-07
CA2872855A1 (en) 2013-11-14
ES2848050T3 (es) 2021-08-05
SG10201603059YA (en) 2016-05-30
KR20200118510A (ko) 2020-10-15
SG10201914117QA (en) 2020-02-27
KR20150023361A (ko) 2015-03-05
EA201492052A1 (ru) 2015-08-31
AU2013260101B2 (en) 2016-10-27
JP2015521176A (ja) 2015-07-27
KR102452803B1 (ko) 2022-10-07
BR112014028094B1 (pt) 2022-03-03
PL2846809T3 (pl) 2021-07-26
JP2019026647A (ja) 2019-02-21
US20200038431A1 (en) 2020-02-06
US11229664B2 (en) 2022-01-25
EP3785720A1 (en) 2021-03-03
EP2846809B1 (en) 2020-10-14
SG11201407340YA (en) 2014-12-30
CL2014003017A1 (es) 2015-07-10
PT2846809T (pt) 2021-02-05
IL235593A0 (en) 2015-01-29
MX2019009437A (es) 2019-10-02
CA3122808A1 (en) 2013-11-14
HK1207574A1 (en) 2016-02-05
BR112014028094A2 (pt) 2020-06-30
JP6177885B2 (ja) 2017-08-09
MX2014013633A (es) 2015-07-06
CN108498532B (zh) 2021-07-23
WO2013169355A1 (en) 2013-11-14
MX370567B (es) 2019-12-17
CA2872855C (en) 2021-07-27
EP2846809A4 (en) 2015-12-30
US20130303481A1 (en) 2013-11-14
EP2846809A1 (en) 2015-03-18
EA029382B1 (ru) 2018-03-30
KR102165348B1 (ko) 2020-10-14
US20180296590A1 (en) 2018-10-18
CN113521093A (zh) 2021-10-22
LT2846809T (lt) 2021-01-25
AU2013260101A1 (en) 2014-12-18
US20130323230A1 (en) 2013-12-05
US20220354882A1 (en) 2022-11-10
JP6448694B2 (ja) 2019-01-09
HUE053247T2 (hu) 2021-06-28
JP2017105850A (ja) 2017-06-15
US9271999B2 (en) 2016-03-01
DK2846809T3 (da) 2021-01-18
US20160213706A1 (en) 2016-07-28
CN104411316A (zh) 2015-03-11
CN104411316B (zh) 2018-05-01

Similar Documents

Publication Publication Date Title
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2017003024A1 (es) Tratamiento para el cancer a traves de la manipulación de microflora comensal
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2015000711A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.
EA201400178A1 (ru) Лечение рака молочной железы
CL2015000873A1 (es) Métodos para el tratamiento del síndrome de alport.
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
CL2014001858A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
CO7020879A2 (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca
CL2015002591A1 (es) Entidades químicas.
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
ES2897914T8 (es) Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos
BR112014005091A2 (pt) composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
BR112014030416A2 (pt) composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção.
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2015000926A1 (es) Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.